Uncertainty Hinders Compliance With EU Rules On R&D On Biological Resources
Executive Summary
Bart Van Vooren explains why pharmaceutical and medical device companies are finding it difficult to comply with the Nagoya Protocol and why they must get involved with the drafting of coming guidelines.